Entera Bio Announces $10 Million Private Placement Financing

Entera Bio ( (ENTX) ) has provided an update.

On April 1, 2026, Entera Bio entered into a Securities Purchase Agreement with funds affiliated with BVF Partners LP for a $10 million private placement of 7,827,789 units, each comprising ordinary shares or pre-funded warrants and accompanying ordinary share warrants, which closed on April 2, 2026. The financing, structured with ownership caps and staged warrant exercisability, is intended to fund initiation of a phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and general corporate needs, with a related registration rights agreement committing Entera to register the resale of the underlying shares.

The most recent analyst rating on (ENTX) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.

Spark’s Take on ENTX Stock

According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.

The score is held down primarily by weak financial performance (shrinking revenue, persistent losses, and ongoing cash burn) and bearish-to-neutral technicals (below key moving averages with negative MACD). Offsetting factors include a low-debt balance sheet and positive corporate milestones (FDA-aligned, streamlined Phase 3 plan and partnership expansion), but valuation support is limited due to loss-making status and no dividend.

To see Spark’s full report on ENTX stock, click here.

More about Entera Bio

Entera Bio Ltd., an Israel-based biopharmaceutical company, focuses on developing orally administered therapies, including EB613, for conditions such as osteoporosis. The company targets postmenopausal women with osteoporosis as a key market segment, positioning itself in the bone health and endocrine-related therapeutic space.

Average Trading Volume: 216,382

Technical Sentiment Signal: Sell

Current Market Cap: $58.74M

See more data about ENTX stock on TipRanks’ Stock Analysis page.